Kong Fan-biao, Wang Xiao-tong, Xie Yu-bo, Xiao Qiang
Department of Surgery, the First Affiliated Hospital, Guangxi Medical University, Nanning 530021, China.
Email:
Zhonghua Zhong Liu Za Zhi. 2013 Sep;35(9):655-9.
To study the effects of E2F-1-silencing lentivirus vector on the growth and chemoresistance of subcutaneous human gastric cancer in nude mice.
Thirty-six nude mice were inoculated subcutaneously with chemoresistant SGC-7901/DDP cells to establish subcutaneous tumor models of gastric carcinoma. The mice were randomly divided into E2F-1/RNAi-LV group, LV-scrRNAi group and PBS group (n = 12). E2F-1/RNAi-LV, LV-scrRNAi or PBS (0.1 ml per time) was injected into the mice, respectively, every two days. The nude mice received an intraperitoneal injection of cisplatin (25 mg/kg) every two days. The tumor volume was measured and histopathological changes of the tumors were observed by HE staining. The expressions of E2F-1, c-Myc, survivin, MDR1 and MRP were detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot. Apoptosis in tumor xenografts was determined by in situ TUNEL labeling technique.
The mean tumor growth rate of the E2F-1/RNAi-LV group was significantly slower than that of the LV-scrRNAi and control groups (P < 0.05). The tumor volume of the E2F-1/RNAi-LV group was (745.13 ± 154.42)mm(3), significantly lower than that of the LV-scrRNAi and PBS groups (P < 0.05). Compared with that in the LV-scrRNAi and PBS groups, the expressions of mRNA and protein of E2F-1, c-Myc, survivin, MDR1 and MRP were significantly decreased in the E2F-1/RNAi-LV group (P < 0.05). The apoptotic rate in the E2F-1/RNAi-LV treatment group was (27.5 ± 9.7)%, significantly higher than (7.0 ± 1.1)% in the LV-scrRNAi group and (7.3 ± 1.2)% in the PBS group (P < 0.05).
Intra-tumoral injection of E2F-1/RNAi-LV shows significantly inhibitory effect on the tumor growth and chemoresistance of subcutaneous human gastric cancer in nude mice.
研究E2F-1沉默慢病毒载体对人胃癌裸鼠皮下移植瘤生长及化疗耐药性的影响。
将36只裸鼠皮下接种耐顺铂的SGC-7901/DDP细胞,建立胃癌皮下肿瘤模型。将小鼠随机分为E2F-1/RNAi-LV组、LV-scrRNAi组和PBS组(n = 12)。分别每两天给小鼠注射E2F-1/RNAi-LV、LV-scrRNAi或PBS(每次0.1 ml)。每两天给裸鼠腹腔注射顺铂(25 mg/kg)。测量肿瘤体积,通过HE染色观察肿瘤的组织病理学变化。采用半定量逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹法检测E2F-1、c-Myc、survivin、MDR1和MRP的表达。采用原位TUNEL标记技术检测肿瘤异种移植中的细胞凋亡情况。
E2F-1/RNAi-LV组的平均肿瘤生长速率明显慢于LV-scrRNAi组和对照组(P < 0.05)。E2F-1/RNAi-LV组的肿瘤体积为(745.13 ± 154.42)mm³,明显低于LV-scrRNAi组和PBS组(P < 0.05)。与LV-scrRNAi组和PBS组相比,E2F-1/RNAi-LV组中E2F-1、c-Myc、survivin、MDR1和MRP的mRNA和蛋白表达明显降低(P < 0.05)。E2F-1/RNAi-LV治疗组的凋亡率为(27.5 ± 9.7)%,明显高于LV-scrRNAi组的(7.0 ± 1.1)%和PBS组(7.3 ± 1.2)%(P < 0.05)。
瘤内注射E2F-1/RNAi-LV对人胃癌裸鼠皮下移植瘤的生长及化疗耐药性具有明显的抑制作用。